[
  {
    "source": "world_health_organization",
    "year": 2024,
    "type": "report",
    "title": "Report of the Sixth Meeting of the WHO Technical Advisory Group on Diabetes: Virtual Meeting, 24-25 June 2024",
    "file_name": "tagd_sixth_meeting_report_june_2024.pdf"
  },
  {
    "source": "diabetesjournals_org",
    "year": 2023,
    "type": "guideline",
    "title": "Standards of Care in Diabetes—2023",
    "file_name": "standards_of_care_in_diabetes_2023.pdf"
  },
  {
    "source": "diabetesjournals_org",
    "year": 2024,
    "type": "guideline",
    "title": "Standards of Care in Diabetes—2024",
    "file_name": "standards_of_care_in_diabetes_2024.pdf"
  },
  {
    "source": "diabetesjournals_org",
    "year": 2025,
    "type": "guideline",
    "title": "Standards of Care in Diabetes—2025",
    "file_name": "standards_of_care_in_diabetes_2025.pdf"
  },
  {
    "source": "diabetesjournals_org",
    "year": 2024,
    "type": "research_paper",
    "title": "Optimal Dose and Type of Physical Activity to Improve Glycemic Control in People Diagnosed With Type 2 Diabetes: A Systematic Review and Meta-analysis",
    "file_name": "optimal_dose_type_physical_activity_type_2_diabetes_2024.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2020,
    "type": "guideline",
    "title": "Diagnosis and Management of Type 2 Diabetes (HEARTS-D)",
    "file_name": "diagnosis_and_management_of_type_2_diabetes_2020.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2018,
    "type": "guideline",
    "title": "Guidelines on Second- and Third-line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Non-pregnant Adults with Diabetes Mellitus",
    "file_name": "guidelines_on_second_and_third_line_medicines_and_type_of_insulin_2018.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2013,
    "type": "guideline",
    "title": "Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy",
    "file_name": "diagnostic_criteria_and_classification_of_hyperglycaemia_first_detected_in_pregnancy_2013.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2024,
    "type": "guideline",
    "title": "Guidance on Global Monitoring for Diabetes Prevention and Control: Framework, Indicators and Application",
    "file_name": "guidance_on_global_monitoring_for_diabetes_prevention_and_control_2024.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2024,
    "type": "report",
    "title": "The Global Diabetes Compact - Progress in Supporting Its Workstreams: Technical Report",
    "file_name": "the_global_diabetes_compact_progress_in_supporting_its_workstreams_2024.pdf"
  },
  {
    "source": "diabetesjournals_org",
    "year": 2024,
    "type": "research_paper",
    "title": "A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes",
    "file_name": "methodological_framework_meta_analysis_glp1_sglt2_2024.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2022,
    "type": "toolkit",
    "title": "Toolkit for Developing a Multisectoral Action Plan for Noncommunicable Diseases: Module 4 – Developing an Implementation Plan",
    "file_name": "toolkit_for_developing_multisectoral_action_plan_ncds_module_4_2022.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2016,
    "type": "report",
    "title": "Global Report on Diabetes",
    "file_name": "global_report_on_diabetes_2016.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2022,
    "type": "toolkit",
    "title": "Toolkit for Developing a Multisectoral Action Plan for Noncommunicable Diseases: Module 5 – Evaluating the Implementation",
    "file_name": "toolkit_for_developing_multisectoral_action_plan_ncds_module_5_2022.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2022,
    "type": "toolkit",
    "title": "Toolkit for Developing a Multisectoral Action Plan for Noncommunicable Diseases: Overview",
    "file_name": "toolkit_for_developing_multisectoral_action_plan_ncds_overview_2022.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2022,
    "type": "toolkit",
    "title": "Toolkit for Developing a Multisectoral Action Plan for Noncommunicable Diseases: Module 1 - Conducting a Comprehensive Assessment",
    "file_name": "toolkit_for_developing_multisectoral_action_plan_ncds_module_1_2022.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2022,
    "type": "toolkit",
    "title": "Toolkit for Developing a Multisectoral Action Plan for Noncommunicable Diseases: Module 2 - Establishing Stakeholder Engagement and Governance Mechanisms",
    "file_name": "toolkit_for_developing_multisectoral_action_plan_ncds_module_2_2022.pdf"
  },
  {
    "source": "world_health_organization",
    "year": 2022,
    "type": "toolkit",
    "title": "Toolkit for Developing a Multisectoral Action Plan for Noncommunicable Diseases: Module 3 - Establishing a Framework for Action",
    "file_name": "toolkit_for_developing_multisectoral_action_plan_ncds_module_3_2022.pdf"
  },
  {
    "source": "diabetesjournals_org",
    "year": 2024,
    "type": "research_paper",
    "title": "Type 2 Diabetes Remission: A New Mission in Diabetes Care",
    "file_name": "type_2_diabetes_remission_new_mission_2024.pdf"
  },
  {
    "source": "diabetesjournals_org",
    "year": 2024,
    "type": "guideline",
    "title": "Introduction and Methodology: Standards of Care in Diabetes—2024",
    "file_name": "introduction_and_methodology_standards_of_care_in_diabetes_2024.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2015,
    "type": "evidence_summary",
    "title": "Diabetes Mellitus Type 1 and Type 2: Insulin Glargine Biosimilar (Abasaglar)",
    "file_name": "diabetes_mellitus_type_1_and_type_2_insulin_glargine_biosimilar_abasaglar_2015.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2014,
    "type": "technology_appraisal_guidance",
    "title": "Canagliflozin in Combination Therapy for Treating Type 2 Diabetes",
    "file_name": "canagliflozin_in_combination_therapy_for_treating_type_2_diabetes_2014.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2023,
    "type": "quality_standard",
    "title": "Type 2 Diabetes in Adults",
    "file_name": "type_2_diabetes_in_adults_2023.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2016,
    "type": "technology_appraisal_guidance",
    "title": "Canagliflozin, Dapagliflozin, and Empagliflozin as Monotherapies for Treating Type 2 Diabetes",
    "file_name": "canagliflozin_dapagliflozin_and_empagliflozin_as_monotherapies_for_treating_type_2_diabetes_2016.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2022,
    "type": "guideline",
    "title": "Type 1 Diabetes in Adults: Diagnosis and Management",
    "file_name": "type_1_diabetes_in_adults_diagnosis_and_management_2022.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2013,
    "type": "evidence_summary",
    "title": "Type 2 Diabetes: Insulin Degludec",
    "file_name": "type_2_diabetes_insulin_degludec_2013.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2015,
    "type": "evidence_summary",
    "title": "Type 2 Diabetes Mellitus in Adults: High-strength Insulin Glargine 300 Units/ml (Toujeo)",
    "file_name": "type_2_diabetes_mellitus_in_adults_highstrength_insulin_glargine_300_unitsml_toujeo_2015.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2023,
    "type": "guideline",
    "title": "Diabetes (Type 1 and Type 2) in Children and Young People: Diagnosis and Management",
    "file_name": "diabetes_type_1_and_type_2_in_children_and_young_people_diagnosis_and_management_2023.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2011,
    "type": "public_health_guideline",
    "title": "Type 2 Diabetes Prevention: Population and Community-Level Interventions",
    "file_name": "type_2_diabetes_prevention_population_and_communitylevel_interventions_2011.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2015,
    "type": "technology_appraisal_guidance",
    "title": "Empagliflozin in Combination Therapy for Treating Type 2 Diabetes",
    "file_name": "empagliflozin_in_combination_therapy_for_treating_type_2_diabetes_2015.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2019,
    "type": "guideline",
    "title": "Diabetic Foot Problems: Prevention and Management",
    "file_name": "diabetic_foot_problems_prevention_and_management_2019.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2023,
    "type": "quality_standard",
    "title": "Type 1 Diabetes in Adults",
    "file_name": "type_1_diabetes_in_adults_2023.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2023,
    "type": "guideline",
    "title": "Diabetes in Pregnancy",
    "file_name": "diabetes_in_pregnancy_2023.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2022,
    "type": "guideline",
    "title": "Type 2 Diabetes in Adults: Management",
    "file_name": "type_2_diabetes_in_adults_management_2022.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2022,
    "type": "guideline",
    "title": "Diabetes in Children and Young People",
    "file_name": "diabetes_in_children_and_young_people_2022.pdf"
  },
  {
    "source": "nice_org_uk",
    "year": 2020,
    "type": "guideline",
    "title": "Diabetes in Pregnancy: Management from Preconception to the Postnatal Period",
    "file_name": "diabetes_in_pregnancy_management_from_preconception_to_the_postnatal_period_2020.pdf"
  },
  {
    "source": "cureus",
    "year": 2023,
    "type": "review_article",
    "title": "The Role of Childhood Obesity in Early-Onset Type 2 Diabetes Mellitus: A Scoping Review",
    "file_name": "the_role_of_childhood_obesity_in_early_onset_type_2_diabetes_mellitus_a_scoping_review_2023.pdf"
  }
]